Clay Siegall PhD, who is the partner of the founder of Seattle Genetics, and the company president and CEO as well, is a scientist that has worked for years to find a cure for cancer. Here is a little about him, his life and what he had done so far.
Seattle Genetics was created as a foundation on discovering therapies for cancer treatment that is humane and easily accessible to all. It began in 1998, and in 2011, the FDA approved some of the first products it has released. The first one released was ADCETRIS (R), commonly known as Bretuximab Vedotin. The pharmaceutical company Takeda offered the product in over 65 countries already.
The success rate of this product for curing cancer is staggering. Dr. Segal has been working hard to develop licenses to allow other companies to offer the product as well. It is an exciting endeavor that is encouraging to those that champion the cure for cancer everywhere.
Before Dr Siegall began that journey, he first served Bristol-Myers Squibb Research Institute, working to try to solve the issues around curing cancer. He did this from 1991 to 1997. During that time as well, he worked to solve the problem with cancer at the prestigious National Cancer Institute from 1988 to 1991.
From 1988 to the present day, Dr. Siegall has been on the board of directors for Ultragenyx Pharmaceutical, Washington Roundtable and Alder BioPharmacuticals. From 2013, at the University of Maryland, he won Alumnus of the Year for his computer, natural science and math contributions. Then, in 2012, he won Ernst and Young’s Young Entrepreneur of the year award. His contributions have achieved over 15 patents and 70 publications in the subject area. The future really holds so much for this champion for the cure for cancer.